FI20031191A7 - Monoamiinin takaisinoton estäjä - Google Patents

Monoamiinin takaisinoton estäjä Download PDF

Info

Publication number
FI20031191A7
FI20031191A7 FI20031191A FI20031191A FI20031191A7 FI 20031191 A7 FI20031191 A7 FI 20031191A7 FI 20031191 A FI20031191 A FI 20031191A FI 20031191 A FI20031191 A FI 20031191A FI 20031191 A7 FI20031191 A7 FI 20031191A7
Authority
FI
Finland
Prior art keywords
monoamine reuptake
reuptake inhibitor
monoamine
mammals
methods
Prior art date
Application number
FI20031191A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI20031191L (fi
Inventor
David Taiwai Wong
Edward Louis Mattiuz
John-Michael Sauer
William Joe Wheeler
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23045157&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI20031191(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of FI20031191L publication Critical patent/FI20031191L/fi
Publication of FI20031191A7 publication Critical patent/FI20031191A7/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/48Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
FI20031191A 2001-03-06 2002-02-20 Monoamiinin takaisinoton estäjä FI20031191A7 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27373001P 2001-03-06 2001-03-06
PCT/US2002/003385 WO2002070457A1 (en) 2001-03-06 2002-02-20 Inhibitor of monoamine uptake

Publications (2)

Publication Number Publication Date
FI20031191L FI20031191L (fi) 2003-08-25
FI20031191A7 true FI20031191A7 (fi) 2003-08-25

Family

ID=23045157

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20031191A FI20031191A7 (fi) 2001-03-06 2002-02-20 Monoamiinin takaisinoton estäjä

Country Status (35)

Country Link
US (2) US20040082666A1 (enExample)
EP (1) EP1379492B1 (enExample)
JP (1) JP2004525912A (enExample)
KR (1) KR20030092012A (enExample)
CN (1) CN1229331C (enExample)
AP (1) AP2003002855A0 (enExample)
AT (2) ATE396170T1 (enExample)
AU (1) AU2002245385B2 (enExample)
BR (1) BR0207716A (enExample)
CA (1) CA2440161A1 (enExample)
CH (1) CH695982A5 (enExample)
CZ (1) CZ20032380A3 (enExample)
DE (1) DE60226715D1 (enExample)
DK (1) DK200301267A (enExample)
EA (1) EA005768B1 (enExample)
EC (1) ECSP034760A (enExample)
EE (1) EE200300419A (enExample)
ES (2) ES2201942B2 (enExample)
FI (1) FI20031191A7 (enExample)
GB (1) GB2389851B (enExample)
HR (1) HRP20030710A2 (enExample)
HU (1) HUP0303341A3 (enExample)
IL (1) IL157779A0 (enExample)
LT (1) LT5143B (enExample)
LU (1) LU91038B1 (enExample)
LV (1) LV13119B (enExample)
NO (1) NO20033921L (enExample)
NZ (1) NZ527431A (enExample)
OA (1) OA12494A (enExample)
PL (1) PL363840A1 (enExample)
SE (1) SE526598C2 (enExample)
SK (1) SK10632003A3 (enExample)
TR (1) TR200705146T1 (enExample)
WO (1) WO2002070457A1 (enExample)
ZA (1) ZA200306882B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1229331C (zh) * 2001-03-06 2005-11-30 伊莱利利公司 一元胺吸收的抑制剂
WO2005020976A2 (en) * 2003-08-27 2005-03-10 Eli Lilly And Company Treatment of pervasive developmental disorders with norepinephrine reuptake inhibitors
KR20060121178A (ko) * 2003-12-12 2006-11-28 일라이 릴리 앤드 캄파니 일과성 전신 열감, 충동 조절 장애 및 일반적인 의학상태로 인한 인격 변화 치료용 선택적 노르에피네프린재흡수 억제제
WO2011027359A2 (en) * 2009-07-30 2011-03-10 Matrix Laboratories Ltd Novel process for the preparation of 4-hydroxy atomoxetine
WO2012020418A1 (en) 2010-08-12 2012-02-16 Matrix Laboratories Ltd Novel polymorphs of 4-hydroxy atomoxetine hydrochloride
DE102013022397A1 (de) 2013-12-19 2016-07-07 Metrax Gmbh Vorrichtung zur Unterstützung eines Ersthelfers bei der Herzdruckmassage
GR1008819B (el) 2015-05-22 2016-08-01 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο σκευασμα που περιλαμβανει ατομοξετινη και μεθοδος παρασκευης αυτου
CN107935848B (zh) * 2017-11-21 2020-12-22 中国农业科学院兰州畜牧与兽药研究所 一种六茜素衍生物及其制备方法和应用
JP2022506113A (ja) * 2018-10-31 2022-01-17 アプニメッド,インコーポレイテッド(デラウェア) 睡眠時無呼吸を治療するための方法及び組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
US4018895A (en) 1974-01-10 1977-04-19 Eli Lilly And Company Aryloxyphenylpropylamines in treating depression
US4194009A (en) 1974-01-10 1980-03-18 Eli Lilly And Company Aryloxyphenylpropylamines for obtaining a psychotropic effect
FR2432500A1 (fr) * 1978-02-24 1980-02-29 Roussel Uclaf Nouveaux derives de la benzene propanamine et leurs sels, procede de preparation et application a titre de medicaments
US5112619A (en) * 1985-11-12 1992-05-12 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulation
US4956388A (en) 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
ZA885824B (en) * 1987-08-14 1989-04-26 Merrell Dow Pharma Novel antidepressants
ZA921292B (en) * 1991-02-25 1993-08-23 Lilly Co Eli Treatment of lower urinary tract disorders.
TW514634B (en) 1997-10-14 2002-12-21 Lilly Co Eli Process to make chiral compounds
WO2000058262A1 (en) 1999-03-29 2000-10-05 Eli Lilly And Company Stereospecific method for preparing tomoxetine and intermediates thereof
ATE309196T1 (de) 1999-04-09 2005-11-15 Lilly Co Eli Verfahren zur herstellung von 3-aryloxy-3- arylpropylamine und deren zwischenprodukte
EP1395253A2 (en) * 2000-11-15 2004-03-10 Eli Lilly And Company Treatment of anxiety disorders
CN1229331C (zh) * 2001-03-06 2005-11-30 伊莱利利公司 一元胺吸收的抑制剂

Also Published As

Publication number Publication date
KR20030092012A (ko) 2003-12-03
FI20031191L (fi) 2003-08-25
ATA90422002A (de) 2006-01-15
ATE396170T1 (de) 2008-06-15
US20040082666A1 (en) 2004-04-29
NO20033921D0 (no) 2003-09-04
IL157779A0 (en) 2004-03-28
ES2201942B2 (es) 2004-12-16
SE526598C2 (sv) 2005-10-18
LV13119B (en) 2004-06-20
EE200300419A (et) 2004-02-16
HUP0303341A2 (hu) 2004-01-28
CZ20032380A3 (en) 2004-03-17
AP2003002855A0 (en) 2003-08-20
NO20033921L (no) 2003-11-05
ZA200306882B (en) 2004-12-03
DK200301267A (da) 2003-11-06
EA005768B1 (ru) 2005-06-30
AT414238B (de) 2006-10-15
GB0323169D0 (en) 2003-11-05
US20050209341A1 (en) 2005-09-22
EA200300978A1 (ru) 2004-02-26
HRP20030710A2 (en) 2004-08-31
HUP0303341A3 (en) 2007-03-28
GB2389851B (en) 2005-05-25
NZ527431A (en) 2005-05-27
DE60226715D1 (de) 2008-07-03
JP2004525912A (ja) 2004-08-26
EP1379492A1 (en) 2004-01-14
CA2440161A1 (en) 2002-09-12
WO2002070457A1 (en) 2002-09-12
PL363840A1 (pl) 2004-11-29
LT2003075A (en) 2004-03-25
LU91038B1 (fr) 2003-09-11
US7384983B2 (en) 2008-06-10
OA12494A (en) 2006-05-24
ECSP034760A (es) 2003-10-28
CH695982A5 (de) 2006-11-15
WO2002070457A8 (en) 2004-06-03
SE0302361D0 (sv) 2003-09-03
GB2389851A (en) 2003-12-24
SE0302361L (sv) 2003-09-03
TR200705146T1 (tr) 2008-02-21
ES2305221T3 (es) 2008-11-01
SK10632003A3 (sk) 2004-06-08
CN1229331C (zh) 2005-11-30
EP1379492B1 (en) 2008-05-21
AU2002245385B2 (en) 2007-01-18
LT5143B (lt) 2004-06-25
CN1494526A (zh) 2004-05-05
ES2201942A1 (es) 2004-03-16
BR0207716A (pt) 2004-03-23

Similar Documents

Publication Publication Date Title
NO20005224L (no) BTK inhibitorer og fremgangsmåter for deres identifikasjon og anvendelse
CY2015028I1 (el) Ενας αναστολεας ν-ακυλοσφιγγοσινο γλυκοζυλοτρανσφερασης
MY136892A (en) Deacetylase inhibitors
CY1112487T1 (el) Βραχειας-δρασης ηρεμιστικοι υπνωτικοι παραγοντες για αναισθησια και καταστολη
DK1355889T3 (da) Substituerede triazoldiaminderivater som kinaseinhibitorer
AP1718A (en) 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors
DK1682530T3 (da) Pyrrolsubstituerede indoler som inhibitorer af PAI-1
TR200202194T2 (tr) Poliglütamik asit-kamptotesin birleşikleri ve hazırlama yöntemleri
ATE289640T1 (de) Amidofunktionelle aminopolydiorganosiloxane
CY1105386T1 (el) Βενζοϋλοσουλφοναμιδια και σουλφονυλβενζαμιδινες για χρηση σαν παραγοντες κατα του ογκου
DE60007095T2 (de) Calanolide zur hemmung von btk
ECSP045245A (es) N-aril-2-oxazolidinona-5-carboxamidas y sus derivados
ATE424560T1 (de) Marker für neuromyelitis optica
GB0107383D0 (en) Lipid profile modulation
SE0301650D0 (sv) Novel compounds
FI20031191A7 (fi) Monoamiinin takaisinoton estäjä
MXPA05005484A (es) Metodo para mejorar las propiedaes fisico-quimicas de composiciones bituminosas y novedosas composiciones bituminosas con propiedades mejoradas y sus usos.
BR0112600A (pt) Compostos calcilìticos
UY26556A1 (es) Compuestos calcilíticos
ATE317384T1 (de) Lta4 hydrolase-hemmer
DE60232650D1 (de) Peptiddeformylaseinhibitoren
ECSP982472A (es) Compuestos calciliticos
ATE364037T1 (de) Tryptasehemmer
DOP2002000329A (es) Composicion solida
UY34598A (es) Antranilamidas insecticidas

Legal Events

Date Code Title Description
MA Patent expired